Kyrollis Attalla has identified TIM-3 and TIGIT as viable targets for monotherapy or in conjunction with other immune checkpoint inhibitors in patients with urothelial cancer of the bladder. This evidence concerns the gene HAVCR2 and bladder transitional cell carcinoma.